Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View AQST insider activity ↗

AQSTAquestive Therapeutics, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$83.78M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$44.55MYear ended December 31, 2025
Profit or loss-$83.78MYear ended December 31, 2025
Cash from the business-$52.43MYear ended December 31, 2025
Total assets$132.1MAs of June 30, 2026
Total liabilities$188.69MAs of June 30, 2026
Cash & equivalents$98.49MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$67.43M
2018-12
$52.61M
2019-12
$45.85M
2020-12
$50.83M
2021-12
$47.68M
2022-12
$50.58M
2023-12
$57.56M
2024-12
$44.55M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$44,545,000March 4, 202610-K ↗
January 1, 2024 – December 31, 2024$57,561,000March 4, 202610-K ↗
January 1, 2023 – December 31, 2023$50,583,000March 5, 202510-K ↗
January 1, 2022 – December 31, 2022$47,680,000March 5, 202410-K ↗
January 1, 2021 – December 31, 2021$50,832,000March 31, 202310-K ↗
January 1, 2020 – December 31, 2020$45,849,000March 8, 202210-K ↗
January 1, 2019 – December 31, 2019$52,609,000March 9, 202110-K ↗
January 1, 2018 – December 31, 2018$67,430,000March 11, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 16, 2026

Response SHA-256: 3bdc66938934696ecad7ea83dddb8c52ff6f8163caff400dc82a94f7e5e2ce7c

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.